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One ofthe foremost functional attributes ofthe mammalian kidney in health is its
ability to regulate the excretion of sodium with sufficient precision to allow for the
maintenance of a constant content of sodium in the extracellular fluid (ECF). In
essence, whatever quantity of sodium enters the ECF from dietary intake must be
excreted by the kidney, and this commitment must beupheld regardless ofthe range
over which sodium intake varies. The capability of the kidney to maintain the
equality between excretion rates and acquisition rates of sodium must also be
preserved in the face of advancing nephron loss ifeither salt retention or salt deple-
tion is to be prevented. Thus when the nephron population is reduced progressively
in the course of advancing renal disease, the residual nephrons must increase their
individual excretion rates of sodium in inverse proportion to the glomerular
filtration rate.
The complexity of regulating the excretion rate of sodium in health and the in-
creasing complexity of this regulation in advancing renal disease make it extremely
unlikely that the mechanisms ofcontrol reside entirely within the nephron. Rather,
it seems essential that a biologic control system exists that has the general design
shown in Fig. 1. A detector element is shown that has the capability of monitoring
the rate of sodium entry into the ECF. The evidence is clear that the detector
element does not perceive changes in the concentration of the sodium ion (i.e., it
does not operate as a "sodium electrode"). Rather, it appears that what is detected
is a translocation from the steady state ofsome property ofthe ECF volume.
A widely held view is that the derivative ofECF that is monitored is the "effective
arterial blood volume" and that receptors, possibly sensitive to pressure or volume,
are distributed diffusely throughout small subdivisions of the vascular tree. If de-
tector elements do exist throughout the body, then it becomes essential that there be
an integrator element, presumably located in the central nervous system and having
the ability to collate the messages arising from the multiple detector components.
The basis for this becomes evident when one examines the potential impact on a so-
dium control system imposed by the sequestration of extracellular fluid in a lo-
calized area of the body. If, for example, there is localized edema formation in one
limb, the detector elements in that limb would see an expanded ECF volume, which
would necessitate an increase in the rate of sodium excretion by the kidney.
However, the effective ECF volume in the rest of the body would be diminished by
virtue of the loss of fluid into the affected limb, and detector elements in the
nonaffected areas would see a decrease in ECF volume, which would be interpreted
as a need to decrease the rate of sodium excretion. An integrator element would
analyze the various stimuli arising from all of the detector elements throughout the
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FIG. 1. Biologic control system for the regulation ofexternal sodium balance.
body and would then establish the nature oftheinformation to be transmitted to the
kidney, theend-organ in the system.
In Fig. 1, an arrow is shown leading from the integrator to the effector element.
The nature ofthis arrow is the subject ofintense interest, scrutiny, and investigation
throughout the world. It is clear that aldosterone exercises an important influence
over the capacity of the nephron to transport sodium. It also is clear that the
"physical factors" within the renal parenchyma, including the peritubular capillary
oncotic pressure and peritubular capillary hydrostatic pressure, influence net so-
dium reabsorption in the proximal tubule. An increase in the former will serve to in-
crease net sodium reabsorption; an increase in the latter will serve to decrease net
sodium reabsorption. Both forces appear to work through influencing the "back
leak" offluid from the peritubular capillary surface ofthe epithelial cells through in-
tercellular channels into the tubular fluid. It appears, however, that even marked
changes in proximal tubular sodium reabsorption have little influence on the ulti-
mate delivery of sodium into the urine (1-6). Thus, the influence ofphysical factors
on theday-to-day regulation of sodium excretion remains to be determined. Finally,
changes in glomerular filtration rate do not provide an adequate explanation for the
modulation ofsodium excretion.
The precision with which sodium excretion is regulated in health has been
responsible for the view that at least one additional factor (over and above changes
in aldosterone activity, physical factors, and GFR) must be involved in the effector
end of the control system. Current attention is being directed to the possibility that
this factor is hormonal in nature, and that its principal effect is to inhibit tubular so-
dium reabsorption, thereby increasing the rate ofsodium excretion. Most investiga-
tors have chosen to focus their search for the so-called "natriuretic hormone" on
normal animals or man subjected to varying degrees of acute and chronic ECF
volume expansion.
The work in our laboratories in search of the same hormone was initiated several
years ago using uremic animals and man, and the rationale for this approach will be
sketched briefly. The change in the biology of sodium excretion imposed by any
renal disease that destroys nephrons is predictable and progressive. With normal
renal function and a given intake of salt, excretion of sodium is shared by ap-
proximately two million nephrons. After the onset of a progressive form of chronic
renal disease, if salt intake remains unchanged, the rate ofexcretion ofsodium must
fall below the rate of acquisition each time GFR falls, thus, transient sodium reten-
tion will ensue and will persist until the excretory contribution ofthe surviving neph-
rons is readjusted upward. In Fig. 2, the change in the rate of excretion of sodium
per nephron (expressed as fractional sodium excretion or FENA) throughout the
natural history ofchronic renal disease is shown schematically. FENarises each time
GFR falls. Also shown in the figure is the fact that the increment in FENamust re-
late to a concomitant and parallel rise in "natriuretic activity." If the natriuretic
forces include a natriuretic hormone, then the concentration of this hormone in the
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FIG. 2. Effects of reduction of glomerular filtration rate (GFR) at constant sodium intake on frac-
tional sodium excretion and natriuretic activity. (Courtesy ofExcerptaMed., Amsterdam.)
blood may well increase with each permanent reduction in GFR, and in the ad-
vanced stages of chronic renal disease, the levels of the hormone in the circulation
could exceed greatly those achieved in normal subjects or animals subjected even to
heroic degrees of volume expansion. It is this line of reasoning that provided the
theoretical basis for the use of patients and animals with chronic uremia in the
search for a natriuretic hormone. Implicit in the approach is the view that if a
natriuretic hormone can be identified in biologic fluids of uremic subjects, it must
also exist, albeit in considerably lower concentrations, in normal subjects.
The first bioassay system that we employed was an indirect one, namely, the
uptake of para-aminohippurate (PAH) by rabbit and rat kidney cortical slides (7).
There was previous evidence that uremic serum inhibited the uptake of PAH by
kidney slices (8,9), and because the transport ofPAH in vitro appears to belinked to
sodium transport, we attempted to isolate the fraction of uremic serum that
contained the PAH inhibitor. In Fig. 3, an elution pattern obtained by filtering
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FIG. 3. Elution pattern of human serum obtained with a 10-mM ammonium acetate solution on a
column packed with Sephadex G-25. The absorbance at 280 my (left abscissa) and the specific
conductance (right abscissa) are indicated by solid and broken lines, respectively. The fraction routinely
used for assay isdepicted by theheavy line. (Courtesy ofJ. Clin. Invest.)
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uremic serum through Sephadex G-25 and using 0.01 M ammonium acetate as the
buffer is shown. The effluent solution was characterized by monitoring both the UV
absorption at 280 nm and the specific conductance of the successive fractions. The
inhibitor of PAH uptake was contained in a fraction of eluate that appeared im-
mediately after the major peak of sodium, urea, and creatinine. The same gel
filtration fraction from the serum ofnormal individuals failed to inhibit PAH uptake
(10).
For many reasons, the PAH system was deemed too imprecise to serve as a
definitive bioassay, and thus, efforts were made to develop a more specific bioassay
system. Two such systems were developed. The first employs the isolated frog skin
or urinary bladder of the toad. Both of these anuran membranes transport sodium
transepithelially, and the net rate of sodium transport can be quantitated simply by
measuring the short-circuit current. The second bioassay system involves the
measurement of sodium excretion by the rat kidney. In the anuran membrane, the
effects on short-circuit current of the addition of a test fraction to the Ringer's so-
lution bathing the blood side of the membrane are measured. In the rat, the effects
ofthe infusion ofthe test fraction intravenously on the rate ofsodium excretion are
determined.
In Fig. 4, a representative experiment is shown in which the gel filtration fraction
from a uremic patient is added to the inside (i.e., blood) surface of an isolated frog
skin. During the equilibration period, both the short-circuit current (SCC) and the
transepithelial potential difference (P.D.) were stable. After addition ofthe fraction,
the SCC and the P.D. began to fall, and the decrements continued until the Ringer's
solution containing the plasma fraction was removed and replaced by fresh
Ringer's. With the removal ofthe inhibitory fraction, both SCC and P.D. increased
towards their control levels. The samegel filtration fraction from normal serum had
no significant inhibitory effect on sodium transport by either the toad bladder or the
frog skin (l1).
A representative experiment using the unanesthetized rat subjected to a reduction
of renal mass of approximately 75% is shown in Fig. 5. After several control
clearance periods, during which GFR and absolute and fractional sodium excretion
were measured, 1 ml ofthe gel filtration fraction shown in Fig. 3 and obtained from
the serum ofa uremic patient was infused intravenously over a 10-min interval. This
quantity offraction is the equivalent ofthe amount ofnatriuretic material contained
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FIG. 4. Effects of the Serum fraction from a patient with chronic uremia on short-circuit current
(SCC) and potential difference (PD) across the isolated frog skin (Courtesy ofJ. Clin. Invest.).
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FIG. 5. Effects of the serum fraction from a patient with chronic uremia on absolute sodium excretion
(UNaV), fractional sodium excretion (FENa), and glomerular filtration rate (GFR) in the assay rat. The
dotted line indicates the mean base-line control values observed before infusion of the fraction. The solid
lines depict the absolute values for each clearance period before and after infusion ofthe fraction.
in 10 ml of original serum, assuming no loss in any of the preparative procedures.
GFR and sodium excretion then were followed over the ensuing 60-min interval.
There was no change in GFR, nor have any consistent changes been observed in
renal plasma flow, filtration fraction, or blood pressure. However, both absolute and
fractional sodium excretion increased, peaking approximately 40 min after injection
of the fraction. Values then fell back toward the control level. With the identical
protocol, the same gel filtration fraction from normal individuals on an average salt
intake produced no significant change in either absolute or fractional sodium excre-
tion rates (12).
The demonstration of a natriuretic factor in the serum fraction of chronically
uremic patients, and subsequently ofchronically uremic dogs (13), coupled with the
inability to detect the presence of the factor in normal subjects and dogs is consis-
tent with the thesis that the active material could play a physiologic role in modu-
lating sodium excretion in uremia. However, the possibility that the factor is a
nonphysiologic "toxin" retained in the blood due to failure ofexcretion could not be
excluded. Consequently, studies were undertaken using urine of chronically uremic
patients and dogs and employing the same gel filtration technique employed for
serum. Fig. 6 compares the effects of the fraction from uremic patients and normal
subjects on sodium transport by the toad bladder. With the normal fractions there
was no inhibition ofshort-circuit current; indeed, slight stimulation was observed. In
contrast, the uremic fractions produced inhibition of SCC, which was apparent
within 10 min of addition of the fraction and continued over a 60-min period of ob-
servation (14). Similar data have recently been obtained by using the fraction
derived from the urine of chronically uremic dogs (15). The urine fraction from
uremic patients and dogs was also found to be natriuretic in the rat (15, 16). Thus,
not only is there increased activity ofthe natriuretic factor in uremic serum, but the
factor also is excreted in increased quantity in the urine of patients and dogs with
low GFRs. The increased excretion rate precludes the possibility that the retention
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FIG. 6. Mean changes, + SE, in short-circuit current (SCC) across the isolated toad bladder during
exposure to urine fractions from normal subjects and patients with chronic uremia.
of the factor in the blood is due to failure of its excretion. Rather, the data require
either that the factor is produced in increased quantity in uremia and/or that its bio-
logic half-life is prolonged.
The degree ofnatriuresis produced by the factor in the rat was next shown to be a
function of the amount of material administered. Fig. 7 depicts a dose-response
curve. The initial natriuresis occurred in response to the administration of the
quantity ofnatriuretic factor harvested from a 2-hr sample ofurine. Sodium excre-
tion increased by approximately 2 uequiv/min. After 1 hr, a tenfold concentrate of
the same material was given intravenously. As can be seen in Fig. 7, the natriuretic
response was striking. Similar changes occur in fractional sodium excretion (16);
moreover, dose-response relationships also have been observed using serum frac-
tions.
Quite recently, studies have been performed using the isolated perfused cortical
collecting tubule ofthe rabbit. When thenatriuretic factor was added to the solution
bathing the peritubular capillary surface of the isolated tubule, there occurred a
highly significant decrease in intraluminal negativity. When the factor was added to
the perfusate so as to expose the luminal surface of the tubule to its effects, no
change in P.D. was observed. The same fraction from normal subjects produced no
effects when added to either the luminal or contraluminal solution. Finally, the
decrease in intraluminal negativity has been associated with inhibition ofnet sodium
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FIG. 7. Dose-response experiment in the assay rat with the urine fraction from a uremic patient. The
first arrow (*) represents the injection ofthe vectorharvested from a 2-hr urine sample, the second arrow
(**) represents the injection ofa tenfold concentrate ofthe same material.
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reabsorption due to a decrease in efflux (i.e., transport from lumen to bath), with no
effect on the leak of sodium back into the tubular fluid from the peritubular surface
(17).
The data thus far indicate that a natriuretic factor exists in the serum and urine of
chronically uremic patients and dogs with high rates offractional sodium excretion,
that the same factor cannot be detected in nonuremic patients and dogs with low
rates offractional sodium excretion with the available bioassay techniques, and that
the rate of production of the factor and/or its biologic half-life is increased in
uremia.
The next step in seeking the answer as to whether or not this factor is a
component part ofthe sodium control system involved examining its relationship to
the concurrent patterns of sodium excretion. Still restricting the search to chronic
uremia, two sets of data were obtained in support of such a relationship. The first
was made possible by the availability of a group of patients with far advanced
chronic uremia (mean GFR approximately 4 ml/min) who did not exhibit the high
rates of sodium excretion per nephron seen in the typical patient with chronic
uremia. These patients were not only uremic but nephrotic. Thus, despite their low
GFRs, they had high rates of protein excretion, hypoalbuminemia, and marked
edema formation. Indeed several of the patients had virtually no sodium in their
urine. Gel filtration fractions of serum and/or urine were examined in the subjects,
and the results are shown in Fig. 8. The typical response of the natriuretic uremic
patient is included for comparison. Despite all of the chemical stigmata of chronic
uremia, the "natriuretic" fraction of serum or urine from the nephrotic patients
produced no increase in either absolute or fractional sodium excretion in the rat
(16).
The second experiment designed to test the relationship between the natriuretic
factor and sodium excretion was performed in two groups of dogs in which renal
mass was reduced in sequential steps so as to decrease GFR from normal values to
values ofapproximately 5-10 ml/min (13). Onegroup ofanimals was maintained on
a constant sodium intake of 120 mequiv/day. In the other group, sodium intake was
initially set at 120 mequiv/day; but each time renal mass was reduced, sodium in-
take was decreased in exact proportion to the measured fall in GFR. By this tech-
nique, which we have termed "proportional reduction of solute," or PRSNa, the rise
in fractional sodium excretion that typically attends the fall in GFR in advancing
renal disease is obviated, and even at very lowlevels ofGFR, values for FENaremain
at less than 0.5%. The comparison ofthe bioassay results using the serum fractions
1.5 -1.5
1.0 1.0 a
-AV0.5 FE0A5
-A1 .i0 10 0ITP -15-
-1.5 -.
FIG. 8. Mean changes, ± SE, in absolute sodium excretion (AUNaV) and fractional sodium excretion
(AFENa) produced by serum fractions from patients with chronic uremia in the absence (left bars) and in
the presence (right bars) ofthe nephrotic syndrome (Courtesy ofJ. Clin. Invest.).
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FIG. 9. Mean changes, ± SE, in sodium excretion produced by the serum fraction from two groups of
uremic dogs with different salt intakes. Group I was maintained on a constant salt intake of 120 mequiv/
day. Group II was subjected to the PRS Na regimen (see text).
from the two groups of dogs is shown in Fig. 9. In the animals maintained on the
constant salt intake, a significant natriuretic response was induced in the bioassay
rats. In the animals maintained on the PRSNaregimen, no significant natriuresis was
observed; and the difference between the constant salt intake group and the PRSNa
group was statistically significant.
The foregoing experiments added one additional link to the chain ofevidence sup-
porting a physiologic role for the natriuretic factor. However, the onus of working
with uremic serum and urine fractions remained, and the possibility still could not
rigorously be excluded that the material was either unique to the uremic state or a
"toxin" with some fortuitous relationship to the dictates of sodium excretion. The
next essential step, therefore, was to demonstrate the presence of the natriuretic
factor in normal dogs. Efforts have been made to accomplish thisgoal.
The studies had the following design. Four groups of animals were studied. All
received a synthetic semiliquid diet that was essentially salt-free. To this diet a pre-
determined amount of sodium was added each day. The first group received a total
of 3 mequiv/day of Na, the second 91 mequiv/day, and the third and fourth 258
mequiv/day. In the first and fourth groups, a supermaximal dose of a potent
mineralocorticoid hormone (0.2 mg offludrocortisone a day) was added to the food.
The animals were maintained in metabolic cages on their respective regimens for 4
days, and on the morning of the fifth day, clearance studies were performed and
urine was collected for a 5-hr period for purposes of assaying for natriuretic factor.
The results ofsodium balance data on thesegroups are shown in Fig. 10. In Group I,
negative sodium balance ensued over the 4-day interval, averaging -51 mequiv. In
Group II, there was a modest degree of sodium retention over the 4 days. In Group
III, positive sodium balance averaged 148 mequiv. Finally, in Group IV, positive so-
dium balance averaged 246 mequiv. It is ofinterest that all of the dogs in the latter
group "escaped" from the effects of the mineralocorticoid hormone prior to
collection of urine for bioassay. The results of the bioassays in the rat are shown in
Fig. 11. In the animals on the low salt diet and in the animals on the 91-mequiv/day
sodium intake, no significant natriuresis was observed in the bioassay tests. In the
groups receiving 258 mequiv/day of sodium without or with mineralocorticoid hor-
mone, a significant natriuresis was induced. Similar results were obtained using the
toad bladder assay (18).
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FIG. 10. Four-day cumulative sodium balance on ordinate in four groups of dogs with normal GFR,
maintained on 3, 91, or 258 mequiv/day of sodium. Animals from Groups I and IV received 0.2 mg/day
of fludrocortisone (F). The balance data represent the difference between oral intake and urinary excre-
tion.
Intensive efforts are currently in progress to determine the chemical natureofthe
natriuretic factor. Isolation procedures have been employed on the gel filtration
fraction containing natriuretic activity from both normal and uremic urine. The
techniques include ion exchange chromatography, descending paper chromatog-
raphy, and amino acid analysis. When the active Sephadex G-25 fractions have been
subjected to ion exchange chromatography on Dowex 50, biologic activity con-
sistently has been recovered in a single fraction that contains no free amino acids.
However, after acid hydrolysis, seven amino acids, asp, thr, ser, glu, gly, ala, and leu
or val, have been identified repeatedly. No basic amino acids have been found. Paper
chromatography analysis of the Dowex 50 biologically active fraction has revealed
several UV absorbing spots and chlorine-0-tolidine staining bands but no ninhydrin
positive bands. The results to date suggest that the natriuretic factor obtained from
both uremic and normal urine is the same substance and that it appears to be acidic,
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FIG. 11. Mean changes, ± SE, in sodium excretion in rats produced by the urine fraction from dogs
with normal GFRs. (See text).
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nonvolatile, of low molecular weight, and possibly peptidic in nature. The biologic
activity appears at a nitrogen concentration of2 ,ug/ml ofthe active Dowex fraction
(19).
In summary, studies have been undertaken to determine whether a natriuretic
hormone exists in nature and, if so, what its role is in the modulation of sodium ex-
cretion. The search to date indicates that there is a low molecular-weight substance
in serum and urine ofuremic patients exhibiting a high rate offractional sodium ex-
cretion and that a natriuretic substance, presumably the same as that found in
uremia, is present in dogs with substantial ECF volume expansion induced by the
chronic administration of a high salt diet and a potent mineralocorticoid hormone.
The presence ofthe factor thus appears to correlate with the dictates ofsodium ex-
cretion and/or the concurrent patterns ofsodium excretion. Attempts to isolate and
characterize the nature ofthe active molecule are in progress, and available evidence
suggests that it is a peptide that is unrelated to vasopressin, oxytocin, angiotensin,
and parathyroid hormone.
Future studies will determine whether this natriuretic factor is a key modulator of
the rate ofsodium excretion in health and in diseases associated with increased rates
of sodium excretion per nephron. Future studies also will determine whether a
decrease in the activity of this substance is a concomitant of certain sodium-
retaining states.
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